Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of autologous TIL therapy LN-144 or LN-145 with or without pembrolizumab in solid tumors
2018-001608-12Phase 2Unknown
- Sponsor
- Iovance Biotherapeutics
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of lifileucel, LN-145 and pembrolizumab in melanoma, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 1 more (3 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoints: Objective response rate and Incidence of grade 3 or higher treatment-emergent adverse events. Status: unknown.
02
Drugs
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2018-001608-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001608-12.